Here is the design of a clinical trial:

Official Title: Simultaneous Resection of Pancreatic Cancer and Liver Oligometastasis After Induction Chemotherapy

Included conditions:
- Pancreatic Cancer
- Liver Metastases
- Surgery

Study Armgroups:
- {'label': 'Standard treatment', 'type': 'ACTIVE_COMPARATOR', 'description': 'Patients continue to receive standard chemotherapy.', 'interventionNames': ['Drug: Standard chemotherapy']}
- {'label': 'Surgical exploration', 'type': 'EXPERIMENTAL', 'description': 'Patients receive surgical exploration and synchronous resection of primary pancreatic cancer and liver oligometastasis will be performed.', 'interventionNames': ['Procedure: Synchronous resection of primary pancreatic cancer and liver oligometastasis']}

Interventions:
- {'type': 'PROCEDURE', 'name': 'Synchronous resection of primary pancreatic cancer and liver oligometastasis', 'description': 'Patients undergo surgical exploration. If no extensive metastatic sites are found, the synchronous resection of primary pancreatic cancer and liver metastatic sites will be performed. Adjuvant chemotherapy was recommended, and the regimen selection is recommended to be based on the preoperative chemotherapy.', 'armGroupLabels': ['Surgical exploration']}
- {'type': 'DRUG', 'name': 'Standard chemotherapy', 'description': 'Patients continue to receive standard chemotherapy including folinic acid, fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX), gemcitabine plus nab-paclitaxel, or gemcitabine plus S-1', 'armGroupLabels': ['Standard treatment']}

Primary Outcomes:
- {'measure': 'Real overall survival', 'description': 'Including the time of induction chemotherapy', 'timeFrame': 'Up to 2 years'}

Please estimate the sample size based on the assumption: 
Two-sided log-rank test, significance level 0.05, power 80%, and a 10% drop-out rate.
Study design and sample size
          CSPAC-1 is an open-label, multicentre, prospective, randomised phase III trial evaluating the efficacy and safety of simultaneous resection of the primary tumour and liver metastases after conversion chemotherapy versus standard therapy in pancreatic cancer with liver oligometastasis. The primary endpoint of this study is rOS. Our null hypothesis is that there is no differences in rOS between the operation arm and the control arm. The alternative hypothesis is that there is a difference between the operation arm and the control arm. Based on previous small-sample study results (the expected median survival times are 20.3 months and 14.0 months in the operation arm and the control arm, respectively), the assumption that enrolment will require 60 months and the requirement that the last patient be followed for at least 24 months, a total of 268 patients (134 vs 134) is needed according to PASS 11.0 software (two-sided log-rank test, significance 0.05; power 80%). Considering a 10% drop-out rate, 298 patients are needed. Therefore, we plan to enrol 300 patients (150 per group), which will be sufficient to meet the needs for sample size.